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A B S T R A C T
MicroRNAs (miRNAs) are small RNAs that do not encode for proteins and play key roles in the regulation of gene
expression. miRNAs are involved in a comprehensive range of biological processes such as cell cycle control,
apoptosis, and several developmental and physiological processes. Oxidative stress can affect the expression
levels of multiple miRNAs and, conversely, miRNAs may regulate the expression of redox sensors, alter critical
components of the cellular antioxidants, interact with the proteasome, and affect DNA repair systems. The
number of publications identifying redox-sensitive miRNAs has increased significantly over the last few years,
and some miRNA targets such as Nrf2, SIRT1 and NF-κB have been identified. The complex interplay between
miRNAs and ROS is discussed together with their role in myocardial ischemia-reperfusion injury and the po-
tential use of circulating miRNAs as biomarkers of myocardial infarction. Detailed knowledge of redox-sensitive
miRNAs is needed to be able to effectively use individual compounds or sets of miRNA-modulating compounds
to improve the health-related outcomes associated with different diseases.
1. Introduction: miRNAs and oxidative stress
Oxidative stress can affect the expression levels of multiple
microRNAs (miRNAs) and, conversely, miRNAs can regulate the ex-
pression of redox sensors and alter key components of the cellular an-
tioxidant machinery [1]. This complex network between miRNAs and
oxidative stress act by modulating cell homeostasis. miRNAs are short
RNAs that do not encode for proteins and play key roles in the reg-
ulation of gene expression acting at the post-transcriptional level [1].
miRNAs were firstly identified in C elegans [2,3]. miRNAs are expressed
in nearly all eukaryotic cells and induce gene silencing by binding to
target sites found within the 3′UTR (untranslated region) of the tar-
geted mRNA [1,4]. This interaction prevents protein production by
suppressing protein synthesis and/or by initiating mRNA degradation.
miRNAs are involved in a wide range of physiological processes and
as such miRNA biogenesis and function are tightly regulated at multiple
levels [1,5]. Canonical biogenesis results in miRNAs being encoded as
individual monocistronic genes, as a cluster containing a few to several
hundreds of different miRNAs, transcribed together as polycistronic
transcripts, or in introns of host genes (intronic). Primary pri-miRNAs
transcripts are generated by RNA polymerase II. In the next step, pri-
miRNAs are processed to pre-miRNAs by a nuclear complex, which
includes the Di George critical Region 8 (DGCR8) dimer and the RNASE
III Drosha [6,7]. Pri-miRNAs contained hairpins and 5′ and 3′ flanking
sequences. The microprocessor complex cleaves at the stem of the
hairpin and liberates a pre-miRNAs with a 5'phosphate and a 3′ hy-
droxyl group. The pre-miRNAs are exported to the cytoplasm by
binding to the export receptor Exportin 5 (XPO5) [8–10], where the
RNASE III enzyme Dicer (in humans Dicer functions with a trans-acti-
vation-responsive RNA-binding protein TRBP) cleaves them and gen-
erates a miRNA duplex intermediate. In the last step, one strand of mi-
RNA duplex assembles with a member of the Argonaute (AGO) to form
the RNA-induced silencing complex (RISC). Upon loading of miRNAs
into the RISC complex, the miRNA guides RISC to complementary se-
quences mainly located at the 3'untranslated regions of its target
mRNAs. RISC regulates gene expression through translational repres-
sion (at the early stages) or mRNA degradation (at the later stages)
[11]. Besides the well-established mi-RNA biogenesis pathway, some
non-canonical Drosha-independent or Dicer-independent miRNAs pro-
cessor have been recently described [12–14]. Moreover, several cell
regulatory factors such as phosphorylation [15,16], deacetylation [17],
ubiquitylation [18] and SUMOylating [19], connect miRNAs biogenesis
to different cell signaling pathways. Diverse studies have also revealed
that some miRNAs-transcription factors are redox-sensitive [20–23].
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Alterations in miRNAs expression profiles occur during organ de-
velopment, aging [24], and cell death [25]. miRNA expression is also
changed during the pathophysiology of complex diseases such as in-
flammation [25], cardiac [26,27], and neurodegenerative diseases
[28], and almost all kinds of cancer [22,29,30]. In addition to their role
in regulating gene expression, miRNAs released into body fluids have
emerged as potential serum biomarkers. Circulating miRNAs can be
either bound to serum proteins and lipoproteins or be encircled in ex-
tracellular vesicles including exosomes, microvesicles or apoptotic
bodies [25]. Currently, miRNAs are intensely studied as candidates for
diagnostic and prognostic biomarkers in liver diseases [25,31], myo-
cardial infarction [27,32] and Alzheimer disease [33].
The link between regulatory factors and miRNAs provide an inter-
esting tool to modulate miRNAs biogenesis in certain pathologies
[18,19]. Emerging evidence now suggests that reactive oxygen species
(ROS) modulate some specific miRNAs biogenesis, also called “re-
doximiRs” [34] and that miRNAs target antioxidant responsive ele-
ments and ROS related genes, thus affecting cellular redox status.
During normal oxidative metabolism, there is a constant formation of
oxidative reactive species in the cell, such as ROS and reactive nitrogen
species (RNS). Reactive oxidants include many ROS (such as H2O2,
O2•−, •OH, 1O2, O3, RO2•, RO•) and RNS (such as •NO, •NO2, ONOO−)
[35,36]. Environmental factors, as well as different physiological and
pathophysiological conditions, influence the formation of radical spe-
cies inside the cell. The generation of ROS and RNS elicits oxidative
stress, which includes the oxidation and subsequent functional im-
pairment of lipids, proteins and nucleic acids [37]. Increase in in-
tracellular ROS/RNS has also been associated with cell death, having a
critical role in the induction of apoptosis [38,39].
A significant disruption of redox homeostasis by ROS/RNS and
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Fig. 1. ROS affecting nuclear and cyto-
plasmic processing of miRNAs. miRNA
transcription can be induced by ROS
activating transcription factors (c-Myc,
p53, NF-κB, HIF-1α). HDAC4 does not
directly bind to DNA but suppresses
transcription when bound to a pro-
moter. ROS can affect miRNA biogen-
esis, translocation and maturation
through regulating the activity and ex-
pression of DGCR8, drosha, exportin 5
and the processing enzyme dicer.
(Arrow indicates activation, T arrow
indicates inhibition).
T. Carbonell and A.V. Gomes Redox Biology 36 (2020) 101607
2
antioxidant defense can induce oxidative stress. Under physiological
conditions, there is a balance between factors promoting ROS/RNS
formation and the cellular antioxidant pool [40,41]. The antioxidant
defense system includes molecular antioxidants and enzymes. Anti-
oxidant enzymes are proteins that convert highly reactive species into
less reactive particles: superoxide dismutase (SOD) scavenges radical
superoxide, while catalase (CAT) and glutathione peroxidase (GPX)
detoxify hydroperoxides [42]. A broader look at the ROS/RNS defense
system would include enzymes that are able to repair cellular damage
[43], including enzymes involved in DNA repair and the proteasome, a
system able to recognize and degrade oxidatively-modified proteins
[44]. However, while at relatively high concentrations, ROS/RNS be-
come harmful, at low levels can promote cell proliferation and survival
[41]. Low ROS levels are also needed because ROS are involved in
several signaling pathways [45,46].
A regulatory interplay between miRNAs and redox signaling have
been increasingly reported in the literature over the last decade. While
some redox-sensitive miRNAs [34] are regulated by oxidative stress,
miRNAs can also regulate cellular redox status. Gene silencing by
miRNAs can result in changes in ROS activators and ROS scavengers,
leading to a complex interplay between oxidative stress and miRNA to
modulate cellular redox homeostasis. Research published to date on the
relationship between miRNAs and oxidative stress suggests that:
miRNAs biogenesis can be regulated by cellular redox status.
miRNAs can target ROS generation and modulate antioxidant sig-
naling
miRNAs can interact with the proteasome and act as endogenous
proteasome inhibitors
miRNAs cooperate with ROS to regulate cell fate, as oxidative stress-
induced apoptosis and autophagy and redox regulation of DNA re-
pair systems
miRNAs regulate ROS in many diseases such as myocardial and
cerebral ischemia-reperfusion injury, as well as cancer.
miRNAs involved in cellular redox status as potential targets for
therapeutics and biomarkers
Current concepts about these aspects of miRNA biology are de-
scribed below.
2. miRNAs biogenesis can be regulated by cellular redox status
The biogenesis and regulation mechanisms of miRNAs are displayed
in Fig. 1. Many scientific reports indicate that several miRNAs are
regulated by redox status [34,47,48]. ROS acts by activating related
transcription factors such as c-Myc, p53, Nuclear factor κB (NF-κB) and
hypoxia-inducible factor 1 (HIF-1α) in response to oxidative stress.
Table 1 shows a summary of studies that indicate ROS can regulate
miRNAs through these transcription factors. c-Myc is a transcription
factor involved in oncogenesis, and whose effects have been correlated
with exposure to ROS [49]. c-Myc induces the expression of miR27a/b,
which, in turn, inhibits the expression of nuclear factor-erythroid 2
related factor 2 (Nrf2) worsening the progression of cholestatic liver
injury [50]. P53, a stress-related transcription factor, can be induced by
ROS and activate target genes for protecting the genome stability [49].
The members of the miR-200 family are markedly enhanced in hepatic
cells by hydrogen peroxide (H2O2) treatment. In liver cells, miRNA-
200s are upregulated by oxidative stress-induced p38a-mediated
phosphorylation of Ser33 on p53 [51]. Upregulation of miR-200-3p
under these conditions promotes H2O2-induced cell death [51]. miR-
506 was regulated by p53 and lead to apoptosis in lung tumor cells
[52].
NF-κB transcriptionally regulates several miRNAs. NF-κB is a critical
regulator of pro-inflammatory/stress-like responses that play important
roles in DNA damage response and apoptosis in different cell type
[53,54]. ROS-induced NF-κB upregulates miR-21, promoting cancer
progression [55] and fibrogenesis [56]. Likewise, miR-146a and miR-
125b were overexpressed after ROS-NF-κB activation in human neural
Table 1
ROS-sensitive transcription factors, ROS induced epigenetic modifications of miRNAs, and ROS induced nuclear and cytoplasmatic processing of miRNAs.
ROS inducing model Transcription factor Targeted
miRNAs
Model and outcomes of miRNAs upregulation References
ROS-sensitive transcription factors affecting miRNAs biogenesis
MELAS syndrome NFκ-B activation mIR-9 Negative regulator of GTPBP3, MTO1 and TRMU leading to aggravated
mitochondrial dysfunction in platelet derived cybrids from two patients with
MELAS syndrome
[169]
Leptin-NADPH oxidases NFκ-B activation miR-21 Fibrogenesis in experimental and human Nonalcoholic Steatohepatitis (NASH) [56]
High glucose NFκ-B activation miR-21 Fibroblasts cells. Promotes migration [55]
Inhibited GSH synthesis C Myc overexpression miR-27a/b Liver cancer progression [50]
Aluminium-sulfate NFκ-B activation miR-146a
miR-125b
Human neural cells. Promotes inflammation [57,58]
H2O2 P38/P53 phosphorylation miR-200 Liver cell death by inhibiting p38/p53 feed-back loop [51]
Hypoxia HIF 1-α miR-210
miR-382
miR-145
Regulation of mitochondrial metabolism in human cancer cells and tumors
Proliferation of pulmonary artery smooth muscle
Promotes angiogenesis in human gastric cancer cells





ROS generation P53 activation miR-506 Induced cell apoptosis and decreases viability in lung tumor cells [52]
ROS affecting epigenetic modifications of miRNAs
Hypoxia HDAC4 supression miR-185 Lung epithelial cell death [70]
Glucose deprivation HDAC2 inhibition miR-466h-5p Increased apoptosis mouse cell line [69]
ROS affecting nuclear and cytoplasmatic processing of miRNAs
Hypoxia DICER miR-155 Upregulation of miRNA induce glycolysis in lung alveolar epithelial cells [73]
Chronic Hypoxia DICER miR-185 Downregulation of Dicer-dependent miRNA maintains the induction of HIF-1α and
hypoxia-responsive genes
[74]




Xpo5 and Ago2 mRNA levels are altered in malnourished mice
The levels of 70% and 50% of the miRNAs, were increased in the hippocampus of
LP mice
[78]
Redox state favoring conversion
of Fe(II)





Increase the efficiency of pri-miRNA processing [71]
[72]
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cells [57,58]. The HIF-1α transcription factor is a critical oxygen sensor
and a major regulator of the hypoxic adaptive response [59]. ROS di-
rectly regulate HIF-1α by oxidizing a cysteine amino residue on HIF-1α,
resulting in a stabilization of the protein. HIF-1α regulates the expres-
sion of genes involved in the adaptation to hypoxia, like EPO (ery-
thropoietin) or VEGF (Vascular endothelial growth factor) [60,61].
Likewise, HIF-1α overexpression can regulate the expression of a broad
range of miRNAs, the so called hypoxamiRs [62], which constitute key
regulators of cellular adaptation to hypoxia. Among them: miR-210,
which regulates mitochondrial metabolism [63] and proliferation of
pulmonary smooth muscle [64]; miR-382 which promotes angiogenesis
[65]; and miR-145 which leads protective effects in cardiomyocytes
[66].
ROS can also regulate miRNAs expression through epigenetic
modifications (Table 1). Like protein coding DNA sequences, miRNAs
genes may undergo DNA methylation and histone modifications. Al-
tered epigenetic miRNA expression has been described in cancer cells
[18,67,68]. Reduced activities of histone deacetylases (HDACs) under
oxidative stress can alter miRNAs expression levels. Accumulation of
ROS due to glucose deprivation inhibited HDAC2 in cultured mouse
cells, which increased acetylation and induction of miR-466h-5p,
leading to increased apoptosis [69]. Likewise, hyperoxia suppresses
histone deacetylase 4 (HDAC4) and subsequently affects histone dea-
cetylation, resulting in an elevated miR-185 transcription [70]. Func-
tionally, miR-185 promotes lung epithelial cell death through inducing
DNA damage.
ROS can modulate miRNAs biogenesis at many levels, and several
enzymes and components of miRNA processing machinery can be af-
fected by oxidative stress (Table 1). In the Drosha-DGCR8 complex,
DGCR8 forms a highly stable and active complex with the ferric heme
using two endogenous cysteines as axial ligands [71]. The reduction of
the heme iron to the ferrous state in DGCR8 abolishes the pri-miRNA
processing activity [71,72]. Dicer is a principal component of miRNA
processing machinery that processes precursor miRNAs (pre-miRNAs)
into mature miRNAs. There is evidence that chronic hypoxia promotes
cell glucose metabolism through Dicer regulation of miR-143 and miR-
155 [73] and the induction of hypoxia-responsive genes through Dicer
regulation of miR-185 [74]. The relationship between the redox state
and the complexes processing miRNA may be more widespread. For
example, a mutant p53 inhibited the processing of pri-miRNAs by
Drosha, decreasing the levels of certain mature miRNAs in cells in-
volved in cell cycle and cell proliferation regulation [75]. In addition,
mutant p53 was also reported to suppress DICER1 expression [76].
Deregulation of the miRNA biogenesis pathway is an emerging me-
chanism in neurodegenerative diseases. Loss of Dicer [77], as well as
downregulation of Drosha and DGRC8 were potentially involved in
several neurodegenerative disorders. Moreover, nutritional stress alters
the expression of the Xpo5 (Exportin 5) and Ago2 (Argonaute RISC
Catalytic Component 2) genes in the hippocampus of restricted protein
offspring mice [78].
3. miRNAs can target ROS generation and can modulate
antioxidant signaling
Oxidative stress is typically the result of an imbalance between the
rate of ROS generation, and the ability to detoxify these reactive spe-
cies. Strong experimental evidence exists to support that miRNAs can
regulate ROS generation and alter key components of the cellular an-
tioxidant machinery. The miRNAs affecting ROS production, anti-
oxidants and repair systems are shown in Fig. 2.
NADPH oxidases (NOXs) are a family of membrane-bound enzymes
that oxidize NADPH to produce ROS (either superoxide or hydrogen
peroxide) as the primary species during the catalytic metabolism of
oxygen for a range of host defense and signaling functions [79] and a
target of several miRNAs [80] (Table 2). Enhanced expression of NOX2
isoform has been reported due to miR-34a overexpression in glioma
cells [20] and after exosomes enriched miR-3 in a mouse model of
cardiac injury [27]. However, other miRNAs inducing inhibition of
NOX2 [81] or attenuated NOX4 activity [68] have also been reported.
miR-124-5p is selectively expressed within the central nervous system
(CNS) and is predicted to bind to NOX2 directly. In vivo, miR-124
overexpression improved, whereas miR-124 inhibition aggravated the
injury in a cerebral I/R injury model in rats through middle cerebral
artery occlusion (MCAO) surgery [81] and increased activity of miR-
21a-3p targets and inhibits NOX4 to inhibit tumor formation [68] in
endothelial cells. Proline oxidase (POX) is a mitochondrial inner-
Fig. 2. miRNAs affecting ROS produc-
tion, antioxidants and repair systems.
miRNAs regulate ROS levels by acti-
vating or inhibiting NOX2 (NADPH
oxidase 2), NOX4 (NADPH oxidase 4)
and POX (Proline oxidase) enzymes.
miRNAs can affect ROS levels through
activation or inhibition of antioxidants
including catalase (CAT), superoxide
dismutases (Cu/Zn SOD and MnSOD),
glutathione peroxidase (GPX) and glu-
tathione reductase (GR). miRNAs can
interact with DNA repair systems and
ubiquitin proteasome system, which
both affect the cellular redox status of
the cell. APE1, AP-endonuclease; LIG3,
DNA ligase 3, OGG1, 8-oxoguanine
glycosylase; MGMT, O-6 -methylgua-
nine DNA methyltransferase; PRO,
proline; P5C, pyrroline-5-carboxylate.
(Arrow indicates activation, T arrow
indicates inhibition).
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membrane enzyme that mediates the proline cycle to shuttle redox
equivalents between mitochondria and the cytosol. POX is a miR-23b
target, and in human renal carcinoma tissues, a negative correlation
between miR-23b and POX protein expression has been reported [29].
The list of miRNAs that targets antioxidant enzymes continues to
expand in different experimental models (Table 3). Intracellular and
extracellular Cu/Zn SOD are downregulated by miRNAs in human
bronchial cells [82] and in a model of atrial fibrillation [83], respec-
tively. miR-212 suppressed MnSOD expression in human colorectal
tumor [67]. miR-30b [84], miR-146a [85] and miR-551b [86] de-
creases CAT expression. Glutathione (GSH) is a ubiquitous low mole-
cular antioxidant [87–89]. In a detoxification reaction, two molecules
of GSH react with H2O2 in a GPX catalyzed reaction, giving GSSG, the
disulfide-oxidized form of glutathione, and water. On the other hand,
GSSG is a substrate of the glutathione reductase (GR) enzyme, which
regenerates GSH. miRNAs have been regarded as potential regulators of
glutathione peroxidases expression [90]. Upregulation of miR-181a
[91], miR-185 [92,93] and miR-144 [94] decrease GPX expression,
while miR-214 increase GPX activity [95] and decrease the GR activity
[96]. GSH levels in the CNS show a circadian rhythm; therefore, a role
for miRNA in the generation of the GSH rhythm has recently been
suggested [97].
miRNAs can also target genes that indirectly modulate the
antioxidant effect. Inhibition or suppression of nuclear Nrf2 expression
by miR-27 a/b has been reported in chronic cholestatic liver injury
[50], and by miR-200c [98] in lung cancer cells. Nrf2 is a transcrip-
tional factor that controls cellular redox homeostasis. Nrf2 activates the
transcription of genes that encode antioxidant enzymes, among others.
Diverse miRNAs can decrease (miR-93) [99] or activate (miR-200a,
miR-7, miR-455) [100–102] Nrf2 pathway in different cancer models,
highlighting the importance of modulating the levels of antioxidant
enzymes under tumor processes.
4. miRNAs can interact with the proteasome and act as
endogenous proteasome inhibitors
A recent exciting development in the protein homeostasis field was
the discovery that miR-101 targets and inhibits the protein POMP
(proteasome maturation protein), a protein that is needed for the as-
sembly of constitutive proteasomes and immunoproteasomes [103]. By
inhibiting POMP miR-101 causes impaired proteasome assembly and
reduced activity. It was previously known that miR-101 is reduced in
several cancers [104,105] and restoration of miR-101 inhibits cancer
cell proliferation.
The proteasome is part of the ubiquitin-proteasome system (UPS)
that is responsible for the degradation of more than 60% of intracellular
Table 2
miRNAs that modulate ROS production.
miRNAs Affected ROS producers Effects Model References
Exosomes enriched miR-3 Enhanced NOX2 expression ROS production
Angiogenesis
Mouse model of cardiac injury [27]
Inhibition of miR-21 Decreased NOX2 Lower ROS production Renal inflammation in NAFLD [170]
Up-regulated miR-21a-3p Attenuated NOX4 activity Decreased H2O2 EOMA cells [68]
Decreased miR-23b Enhanced Proline Oxidase ROS production
Apoptosis
Renal tumors [29]
Overexpression of miR-34a Enhanced NOX2 expression ROS production
Apoptosis
Glioma cells [20]
Overexpression of miR-124-5p Inhibits NOX2 Decreased ROS, MDA Improved I/R injury in MCAO rats
Decreased OS in OC-12 cells
[81]
Overexpression of miR-155 Decreased Nfe2l2, Sod1, and
Hmox1
ROS production Induced ROS production in mesenchymal stem cells (MSCs) from
aged mice
[171]




miRNAs that modulate antioxidant expression or activity.
miRNAs Targeted Antioxidant Model References
miR-7 Inhibit Keap1/activates Nrf2pathway Human neuroblastoma cell line [101]
miR-21 Extracellular Cu/ZnSOD inhibition
MnSOD downregulation
Human bronchial epithelial cells [82]
miR 27ab Inhibit Nrf2 expression Chronic cholestatic liver injury [50]
miR-30b Inhibit Catalase expression Retinal pigment epithelial cell line [84]
miR-93 Decrease Nrf2 level Breast carcinogenesis [99]




Primary erythroid progenitor cells
Human neuroblastoma SH-SY5Y cells
Primary erythroid progenitor cells





miR-146a Decrease Catalase expression Human lung cancer cells [85]
miR-181a Decrease GPx expression Rat cardiomyocyte cell line [91]








miR-212 Supress MnSOD expression Colorectal tumor [67]
miR-214 Increase GPx activity
Decreased GR activity
Diabetic nephropathy
Alcohol induced liver injury
[95]
[96]
miR-206 Intracellular Cu/ZnSOD inhibition Canine model of atrial fibrillation [83]
miR-200c Supress Nrf2 expression Lung cancer cells [98]
miR-455 Inhibits Cul3/activates Nrf2 Human osteoblasts [102]
miR-551b Decrease Catalase expression Lung Cancer model [86]
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proteins. The proteasome itself is a large complex that could be dived
up into two parts, the 20S and the 19S, which together form the 26S
proteasome [106,107]. The 20S proteasome is composed of 28 subunits
in a barrel shape structure with four rings (two α and two β rings). The
20S proteasome has three independent proteolytic β subunits (each
occurring in duplicate) with caspase-like (β1), trypsin-like (β2), and
chymotrypsin-like activities (β5) that are responsible for the cleavage of
proteins that enters the proteasome. The 19S complex is the regulatory
complex that is responsible for recognizing poly-ubiquitinated proteins,
removing the ubiquitins attached to proteins targeted for degradation,
and unfolding the proteins for entry into the 20S proteolytic core. In-
hibition of the proteasome is associated with many diseases, including
cardiac diseases, Alzheimer's, Parkinson's, diabetes and others, and
significant inhibition of the proteasome leads to cell death [107].
The proteasome is also very important in reduced intracellular
oxidative stress by degrading oxidized proteins. Another form of the
proteasome, call the immunoproteasome, seems to be optimized for
degrading oxidized proteins [108]. Although not measured im-
munoproteasome activity would also likely decrease if POMP is im-
paired since POMP is also important in the assembly of im-
munoproteasomes. The activity of the proteasome can also be regulated
by oxidative stress. The apoptosis-regulating kinase ASK1 is activated
by oxidative stress (such as H2O2), and can interact with and phos-
phorylate the RPT5 subunit of the 19S complex [109]. Phosphorylation
of the proteasome by ASK1 results in all three activities of the protea-
some being reduced and may play a role in apoptosis [109]. Formation
of a functional proteasome 26S complex is a multifaceted process in-
volving the synthesis of the individual subunits, partial assembly, full
assembly, and then maturation. This latter process in humans requires
POMP, a chaperone that forms the 20S half-structures by (referred to as
16S proteasome precursors) [110–113]. POMP is degraded after pro-
teasome maturation. The cancer cell proliferation that is inhibited by
miR-101 can be rescued by overexpression of POMP. The ability of miR-
101 to inhibit proteasome activity is interesting because the proteasome
inhibitor, bortezomib (which inhibits the β5 proteasome subunit) has
been used as an anti-cancer drug for over a decade [114]. Other reports
also suggest that cancer cells are more vulnerable to proteasome in-
hibition than control cells [115].
While miR-101 is important in redox cellular biology because of its
direct link to regulating proteasome activity and hence the levels of
oxidized protein in a cell, many other miRNAs act by regulating the
Nrf2 pathway. The Nrf2 pathway is one of the most important pathways
for intracellular protection during oxidative stress as Nrf2 regulates the
expression of several cytoprotective and stress-related genes including
thioredoxin (Trx) and HO-1 [116–118]. In healthy cells, Nrf2 is readily
polyubiquitinated by the BCR(KEAP1) ubiquitin ligase complex, and
then becomes a substrate for the 26S proteasome, resulting in low levels
of Nrf2. KEAP1 (Kelch Like ECH Associated Protein 1) is a substrate
adaptor that interacts with Nrf2 and the BCR complex, which under
conditions of oxidative stress, undergoes oxidation of its reactive cy-
steine residues, resulting in Nrf2 dissociating from KEAP1 (Fig. 3)
[119]. Free Nrf2 can translocate to the nucleus where it can interact
with antioxidant response elements (AREs) [120]. In mammalian cells,
most of the genes encoding proteasome subunits, POMP, and other
assembly partners contain AREs [121]. Nrf1 and Nrf2 can upregulate
the expression of proteasome subunits and POMP by binding to the ARE
in response to proteasome inhibition [121,122].
Nrf2 has also been shown to promote biogenesis [123] and regulate
ROS levels in mitochondria via many mechanisms including increasing
the synthesis of NADPH and GSH, regenerating Trx2 and GSH and in-
creasing the detoxification of peroxides by GPx and Prx3 [124]. Pick-
ering et al., 2012 found that the addition of H2O2 induced binding of
Nrf2 to the ARE of the proteasome β5 gene, resulting in increased β5
mRNA levels. Additionally, inducers of Nrf2 also upregulate protea-
some subunits and activity in different cell types [125,126]. As such,
induction of proteasome subunits by the Nrf2-pathway is likely to be an
important way for a cell undergoing oxidative stress to increase its
capacity to remove damaged and oxidized proteins. miR-155 levels
were lower in plasma cells from multiple myeloma (MM) patients when
compared to control patients [127]. Addition of synthetic miR-155
mimics into MM cell lines resulted in increased pro-apoptotic effects
and decreased cell viability. In MM cells resistant to the proteasome
inhibitor, bortezomib, when the miR-155 mimics were added, they
enhanced bortezomib anti-tumor activity. These results suggest that
miR-155, like miR-101 exerts its effect by proteasome inhibition.
Although bortezomib has helped with the management of MM
Fig. 3. miRNAs regulating the Nrf2 pathway.
In healthy cells, Nrf2 is polyubiquitinated by
the KEAP1 ubiquitin ligase complex, be-
coming a substrate for the 26S proteasome.
Under conditions of oxidative stress, KEAP1
undergoes oxidation of its reactive cysteine
residues, resulting in Nrf2 dissociating from
KEAP1. Free Nrf2 can translocate to the
nucleus where it can interact with anti-
oxidant response elements (AREs). CUL3,
cullin-3, KEAP1, Kelch-like ECH-associated
protein 1, Nrf2, nuclear factor-erythroid 2-
related factor 2, Ub, Ubiquitin. (Arrow in-
dicates activation, T arrow indicates inhibi-
tion).
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patients, resistance to bortezomib occurs over time [128]. Using
genome-wide profiling of bortezomib-resistant myeloma cells, MiR-29b
was significantly reduced in bortezomib-resistant cells [128]. Further
investigation showed that miR-29b targeted the proteasome subunit
PSME4 (Proteasome Activator Subunit 4). PSME4 encodes one of the
subunits of the PA200 complex which can replace the 19S complex and
interact with the 20S proteasome. The PA200 has been shown to be
involved in degrading histones following DNA double-strand breaks.
Synthetic miR-29b mimics diminished the growth of myeloma cells,
xenotransplants, and patient tumor cells [128]. These miR-29b mimics
also reduced proteasome activity and has the potential to synergisti-
cally enhance the anti-tumour effects of proteasome inhibitors.
Using a combination of approaches, miR-200c was identified as a
negative regulator of Noxa expression [129]. Noxa is a pro-apoptotic
protein that contributes to p53-mediated apoptosis under certain con-
ditions such as radiation exposure. miR-200c overexpression resulted in
increased susceptibility to bortezomib in several cell lines. When cells
lacking Noxa were used to overexpress miR-200c these cells had greater
apoptosis induced by proteasomal inhibition compared to cells treated
with proteasome inhibitors but without overexpression of miR-200c,
suggesting that miR-200c is an enhancer of bortezomib-induced cell
death. The results also suggest that multiple miRNAs may be working
together acting on different aspects of the proteasome (proteasome
assembly, proteasome subunits, etc.) to intensify the proteasome in-
hibition. Overall, these results suggest that the miRNAs that act by in-
hibiting proteasome activity are good targets for potential anti-cancer
therapeutic strategies.
Recently, in silico tools were used to determine which miRNAs are
involved in oxidative stress regulation [130]. Literature with informa-
tion on miRNAs that changed expression levels in the presence of oxi-
dative stress damage was reviewed and miRNA data extracted and
utilized with several databases and prediction software to gene targets
and pathways of oxidative stress-modulated miRNAs. This approach
allowed the identification of potential miRNAs that will target the
oxidative stress-related miRNA gene targets and pathways. One of the
major pathways identified was the ubiquitination pathway. One ex-
ample of a miRNA affecting the UPS would be miR-501-5p. Autosomal
dominant polycystic kidney disease (ADPKD) cells and tissues show
upregulated miR501-5p, which induces mTOR kinase activation [131].
The mTOR kinase increases the expression of the E3 ubiquitin ligase
MDM2, which ubiquitinates p53, increasing its rate of degradation by
the proteasome. miR501-5p overexpression inhibits mTOR activity and
increases cell proliferation in kidney cells. Reduced expression of
miR501-5p as well as the proteasome and mTOR inhibitors activate
apoptosis and lessens cell growth in autosomal dominant polycystic
kidney disease (ADPKD) cells [131]. Several miRNAs have also been
shown to be associated with both ubiquitination and autophagy, in-
cluding miR-9, miR-16, miR-17, miR-93, miR-101, miR-124, miR-128,
miR-200, miR-429, and miR-497 [130].
5. miRNAs cooperate with ROS to regulate cell fate, as oxidative
stress-induced apoptosis and autophagy and redox regulation of
DNA repair systems
Several miRNAs are involved in redox regulation of DNA damage
and DNA repair pathways (Table 4) [132]. miRNAs play an important
role in regulating mitochondrial signaling pathways, including the
apoptotic pathway [133]. Ionizing radiation (IR) induces the generation
and accumulation of mitochondrial ROS and causes DNA damage,
which ultimately results in apoptosis in bone marrow mesenchymal
stromal cells (BMSCs). The mitochondrial ROS can damage the mi-
tochondria resulting in a dysfunction mitochondrial antioxidant system,
resulting in further ROS buildup. IR is used experimentally to in-
vestigate the effects of radiotherapy, which is commonly performed as
part of the treatment for many malignancies such as cancer. IR induces
miR-22 in many cell types, including bone marrow mesenchymal
stromal cells (BMSCs) [134]. Overexpression of miR-22 increases mi-
tochondrial ROS and cellular apoptosis. Redd1 was found to be a target
for miR-22 and overexpression of Redd1 diminished the role of miR-22
on mitochondrial ROS generation protecting cells from miR-22 induced
cell injury due to IR.
In mouse hippocampal neurons, H2O2 upregulated miR-135b and
miR-708, and their targets were predicted to be involved in DNA re-
combination and protein ubiquitination [132]. miRNA-370-3p was the
most downregulated miRNA in tissues of glioblastoma multiforme
(GBM) chemotherapy cells and temozolomide resistance cells [135]. A
miRNA-370-3p mimic repressed the self-reparative ability of GBM cell
DNA and increased the sensitivity of these cells to temozolomide. The
target gene of miR-370-3p was O(6)-methylguanine-DNA methyl-
transferase (MGMT). toxicity In A549 and H1299 cells, increased miR-
4673 expression due to paclitaxel (PTX) resulted in increased ROS and
apoptosis and reduced cell viability [136]. miR-4673 was found to
target and reduce 8-Oxoguanine-DNA Glycosylase-1 (OGG1). Increased
levels of OGG1 reduced PTX induced ROS, apoptosis and cell death.
Although beyond the scope of this review, many miRNAs are pro-
apoptotic, including miR-34a, miR-144, miR-155, and miR-200, while
others are anti-apoptotic, including miR-210, miR-21, and miR-146a
[137]. Experimental data also suggest that miRNAs can initiate apop-
totic pathways in mitochondria during myocardial ischemia-reperfu-
sion-injury [133].
6. miRNAs and ROS in cancer and myocardial ischemia-
reperfusion injury
Numerous reports provide strong evidence of a reciprocal link be-
tween miRNAs and ROS in cancer [138,139]. However, the role of
miRNAs and ROS in cancer will not be discussed in detail here as
several great recent reviews on that topic are available [140–144]. ROS
generation leads to oxidative DNA damage which has been suggested to
be one of the first steps in the development of tumors [37,40]. ROS
accumulation may activate oncogenic signaling and also control the
Table 4
miRNAs mediated redox regulation of DNA damage and DNA repair pathways.
miRNAs Target Expression Effects References
miR-22 overexpression Reduces Redd1 Promotes mitochondrial ROS, DNA damage, and apoptosis in bone
marrow mesenchymal stromal cells
[134]
Decreased miR-130a Increase APE1 Confers resistence to temozolomide in glioma cells [177]
miR-135b overexpression Not determined May play a role in Alzheimer's disease [132]
miR-185 overexpression Increased the relative apurinic/apyrimidinic (AP) sites
in genomic DNA
Downregulated 14-3-3δ signaling pathway
DNA damage in lung epithelial cells
Induced apoptosis
[70]
miR-200a overexpression Down-modulates OGG1, APE1, LIG3 and XRCC1 Required for repairing 8-OH-dG in senescent primary human
keratinocytes
[178]
Overexpression of miR-370-3p Downregulates MGMT Stimulate sensitization to temozolomide in glioblastoma cells [135]
miR-4673 overexpression Down-modulates OGG1 Required for repairing 8-OH-dG in human lung cancer cell line [136]
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expression of various tumor suppressor genes that results in tumor
progression [145]. Paradoxically, radiation and various chemother-
apeutic agents used to treat cancer mediate their effects through the
production of ROS [39,145]. Several miRNAs behave as regulators of
gene expression by interacting with oncogenic and tumor suppressor
genes that contribute to tumorigenesis. Consistent with this hypothesis,
recurrent genetic and epigenetic alterations of individual miRNA have
been found in several tumors [20,29,135,136].
ROS-sensitive transcription factors affect the biogenesis of miRNAs
with oncogenic roles. For example, ROS generated by p53 dependent
mechanisms can induce the expression of miR-506, resulting in de-
creased viability of lung tumor cells due to apoptosis [52]. It has also
been shown that miRNAs can modify ROS homeostasis during the
process of cancer. In human renal carcinoma tissue a decrease in miR-
23b enhanced proline oxidase protein expression leading to ROS pro-
duction and apoptosis [29]. Silencing miR-517a promotes oxidative
stress in melanoma cells and decreases cell proliferation [146]. Several
miRNA modulations can affect the Nrf2 pathway and modify anti-
oxidant enzymes expression in different cancer models. Enhanced ex-
pression of miR27a/b inhibits Nrf2, thereby worsening the progression
of cholestatic liver injury [50]. In breast cancer cells miR-93 decreases
Nrf2 level [99] and miR-28 reduces the stability of Nrf2, increasing
colony formation [147]. Attempts to modify ROS production in cancer
using mi-RNA as a therapeutic tool have also been reported. The
miRNA-mediated targeting of the NOX family of enzymes decreases
ROS production and reduces cancer aggressiveness [148]. Although the
molecular mechanisms underlying the role of miRNA and ROS in tu-
morigenesis and chemoresistance are better understood than in other
diseases, they are still currently the subject of significant research.
Several reports support a role for miRNAs in myocardial ischemia-
reperfusion (I/R) injury (Table 5) [149]. When a patient is admitted to
the hospital with myocardial ischemia, that patient usually undergoes
re-canalization of the coronary artery to help restore blood supply to
the heart. However, this restoration of the blood supply (re-oxygena-
tion), or reperfusion, can cause oxidative stress and inflammation,
which leads to tissue damage, apoptosis and necrosis of cardiac cells.
Reperfusion injury results in changes in intracellular free Ca2+ con-
centrations and a key regulator of Ca2+ signaling is Ca2+/calmodulin
dependent protein kinase II (CaMKII). CaMKII mediates several sig-
naling pathways in the heart, including hypertrophy, apoptosis, and
heart disease. In H2O2 treated cardiomyocytes, miR-145 targets and
reduced CaMKIIδ protein expression resulting in suppressed ROS-in-
duced Ca2+ increases, which will prevent apoptosis [150].
Oxidative stress following a period of hypoxia causes lipid and
protein oxidations, and DNA damage which could eventually lead to
cell death. In rat heart, using a myocardial I/R injury model of 30 min
ischemia followed by 12h reperfusion, the infarct size, cardiomyocyte
apoptosis, and levels of creatine kinase and lactate dehydrogenase re-
leased were all decreased when miR-22 was overexpressed [151]. One
of the targets of miR-22, CBP (cAMP response element binding (CREB)
binding protein), was inhibited by miR-22 overexpression. Down-
regulation of CBP resulted in decreased Bax and p21 (pro-apoptotic
related genes) and reduced p53 acetylation activity [151]. This data
suggest that miR-22 can inhibit cardiomyocyte apoptosis that occurs
due to I/R injury by inhibiting CBP. miR-374a-5p expression was de-
creased in a myocardial hypoxia/reoxygenation (H/R) H9C2 cell model
and a mouse I/R model [149]. miR-374a-5p over-expression diminished
cardiac cell damage in both in vivo the cell H/R model and the mouse I/
R models of ischemia. miR-374a-5p was found to regulate mitogen-
activated protein kinase 6 (MAPK6) negatively. Increased MAPK6 ac-
tivity inhibited the protective effect of miR-374a-5p in the H9C2 H/R
model [149]. Hence, miR-374a-5p seems to be protective against in
vitro H/R injury and in vivo cardiac I/R injury.
A mouse model of myocardial infarction (MI) showed increased
expression of miRNA-1 [152]. To investigate the role of miRNA-1 on
MI, mouse hearts that underwent MI, as well as sham hearts, were
treated with a miRNA-1 antagomir that inhibited miRNA-1 expression,
miRNA-1 lentiviral vectors that increased miRNA levels or bortezomib
that decrease proteasome activity [152]. miRNA-1 upregulated com-
ponents of the UPS, such as an E3 enzyme and 19S and 20S subunits.
Reduced miRNA-1 levels or inhibiting proteasome activity both les-
sened the left ventricular (LV) end-diastolic diameter and LV mass
Table 5
miRNAs involved in oxidative stress induced Cardiac Ischemia/Reperfusion Injury.
miRNAs Expression Target Effects Model References
miR-1 Upregulated E3 enzyme/19S and 20S proteasome subunits LV end-diastolic diameter and LV mass Mice I/R [152]
miR-19a Downregulated PTEN/PI3K/pAKT Cell injury/apoptosis H9c2 [179]















miR-34a Upregulated SIRT-1 Apoptosis/infarct size Cardiomyocytes [183]
miR-93 Downregulated PTEN/PI3K/pAKT ROS/Cell injury/apoptosis H9c2 [184]
miR-126a-5p Upregulated Hspb8 Cell injury/apoptosis H9c2
Mice I/R
[185]
miR-129-5p Downregulated PI3K/AKT/mTOR Cell injury/autophagy H9c2 [186]
miR-141-3p Upregulated PI3K/AKT Apoptosis H9c2 [187]
miR-142-3p Downregulated TLR4/NFk-B Apoptosis Mice I/R [188]
miR-144 Downregulated FoxO1 Apoptosis H9c2
Rats I/R
[189]
miR-145 Downregulated CaMKIIδ Apoptosis Cardiomyocytes [150]
miR-153 Upregulated Nrf2/HO-1 ROS/apoptosis Cardiomyocytes [160]
miR-181b-5p Upregulated PI3K/AKT Cell injury/apoptosis H9c2
Rats I/R
[190]
miR-181c-5p Upregulated PTPN4 Cell injury/apoptosis H9c2 [191]
miR-208 Downregulated P21 ROS/apoptosis Cardiomyocytes [192]
miR-210 Downregulated AIFM3 ROS/apoptosis Cardiomyocytes [153]
miR-223 Downregulated NLRP3 Inflammation H9c2 [193]





Cell injury/apoptosis H9c2 [194]
miR-711 Upregulated HIF-1α/NF-kB apoptosis H9c2 [195]
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increases that occur due to MI. Together with other experiments per-
formed, these results suggest that UPS component are mediators of the
effects of miRNA-1 on the cardiac remodeling that occurs after MI. It
was disappointing that the latter study did not measure the proteasome
activity after reducing miRNA levels since an increase in proteasome
expression does not always result in increased proteasome activity.
Overexpression of miR-210 in cardiomyocytes reduces ROS pro-
duction and cell death, while lower miR-210 levels increase ROS pro-
duction after hypoxia-reoxygenation [153]. miR-210 targets mi-
tochondrion-associated 3 (AIFM3), an apoptosis-inducing factor, but
miR-210 cardioprotective effects do not seem to be via AIFM3. The
upregulation of miR-210 may be via protein kinase B (Akt) and p53-
dependent pathways since Akt inhibition results in lower miR-210 in-
duction during hypoxia, and p53 overexpression in mouse embryonic
fibroblasts (MEFs) induce miR-210. The miR-210 cardioprotective ef-
fects in cardiomyocytes seem to be through reducing mitochondrial
ROS production and although not investigated may be occurring via
Nrf2. Tingle SJ et al. [154] investigated if dual blockade of miR-24-3p
and miR-145-5p will synergistically upregulate shared target genes
during Human Umbilical Vein Endothelial Cells (HUVECs) I/R injury.
Under hypoxic conditions miR-24-3p, miR-145-5p and ROS production
are upregulated, and heme oxygenase 1 (HMOX1) and SOD1 are
downregulated. miR-24-3p and miR-145-5p were highly expressed in
human kidneys following extended cold ischemia. Inhibition of miR-24-
3p and miR-145-5p before hypoxia-reoxygenation increased HMOX1
and SOD2, and decreased cellular ROS to lower levels than when either
miR-24-3p or miR-145-5p were blocked individually.
An ingredient from the traditional Chinese medicinal plant, Rhodiola
rosea, Salidroside, was found to be protective (increases antioxidant
enzymes, SOD and GSH-Px, reduces ROS and malondialdehyde (MDA)
levels and increased cell viability) against myocardial I/R injury in vitro
and in vivo. This protective effect in H9C2 cells was found to be
mediated by miR-21 as a miR-21 inhibitor reversed the effects of
Salidroside [155].
These changes in miRNA expression occur mainly via modulation
Nrf2, sirtuins, calcineurin/nuclear factor of activated T cell (NFAT), or
NF-κB pathways. Several circulating miRNAs have been reported to be
potential biomarkers of ROS-related cardiac diseases, including myo-
cardial infarction, hypertrophy, ischemia/reperfusion, and heart
failure, such as miRNA-499, miRNA-199, miRNA-21, miRNA-144,
miRNA-208a, miRNA-34a, and others. While a lot of research pub-
lications and reviews suggest that circulating miRNAs are potential
biomarkers for ROS-related cardiac disease and are likely to be good
therapeutic targets because of the number of miRNAs and opposing
actions of some miRNAs, significantly more experimental research is
needed before we will know if miRNAs will be good biomarkers or
therapeutic targets [156].
7. miRNAs and ROS in cerebral ischemia-reperfusion injury
Cerebral I/R injury happens when an ischemic stroke occurs, and is
characterized by swelling of cells, apoptosis and necrosis [157]. The
primary source of ROS in brain tissue comes from NOX2. Data from a
rat I/R injury model and an SH-SY5Y cell hypoxia/reoxygenation (H/R)
model showed that NOX2 is significantly increased [158]. The miR-652
was decreased in both models (I/R and H/R), and the use of a miRNA-
652 agomir (which reduces miR-652 levels) decreased NOX2 expression
and ROS production in brain tissue of the rat cerebral I/R model. miR-
652 overexpression reduced NOX2 expression and ROS generation in
the H/R treated SH-SY5Y cells [158]. These results suggest that miR-
652 is protective against cerebral I/R injury by targeting NOX2.
A cellular model to mimic cerebral I/R injury, called oxygen-glucose
deprivation/reoxygenation (OGD/R), has been used in several studies.
Hippocampal neurons exposed to OGD/R had significantly less miR-
148b-3p expression levels [159]. When miR-148b-3p was over-
expressed in neurons, ROS levels and apoptosis was increased, and cell
viability decreased after OGD/R. Conversely, inhibition of miR-148b-3p
decreased ROS production and apoptosis and improved cell viability
[159]. The miR-148b-3p target was a cytoprotective gene, Sestrin2 and
Nrf2. Inhibition of miR-148b-3p upregulated both Sestrin2 and Nrf2.
Consistent with these results, reducing Sestrin2 or Nrf2 considerably
reversed the protective effect of miR-148-3p-inhibition in OGD/R-in-
jured neurons. Treatment of cardiomyocytes using an oxygen-glucose
deprivation and reoxygenation (OGD/R) cellular model which should
be similar to an I/R model significantly upregulated miR-153 which
resulted in increased ROS production and apoptosis [160]. Cardio-
myocytes were protected from OGD/R treatment injury when miR-153
levels were reduced. Like many other miRNAs, miR-153 targeted Nrf2,
and acts via the inhibiting the Nrf2/HO-1 pathway.
miRNAs are not just regulators of I/R injury in cardiomyocytes but
many other cell types and tissues including neuronal tissue. Various
miRNAs have also been found to be altered in neuronal injury during
cerebral ischemia/reperfusion injury [159]. MiR-153 has also been
shown to be important in regulating neuron survival during cerebral
ischemia/reperfusion (I/R) injury. miR-199a-5p overexpression in
HT22 neurons exposed to OGD/R treatment increased ROS production
and induced apoptosis, while inhibition of miR-199a-5p prevented
OGD/R-induced ROS production and apoptosis [161]. The target gene
for miR-199a-5p was Brahma-related gene 1 (Brg1), which activated
Nrf2/HO-1 signaling. Knockdown of Brg1 levels prevented the miR-
199a-5p inhibition-mediated neuroprotective effect on neurons [161].
Hence the results suggest that lower levels of miR-199a-5p are pro-
tective for neurons exposed to OGD/R-induced injury.
More recent studies suggest that miR-224-3p and miR-10a are also
involved in modulating ROS levels [162,163]. Using the OGD/R model
in N2a cells, miR-224-3p overexpression reduced ROS and apoptosis
due to its interaction with the FAK family‐interacting protein (FIP200)
[162]. The effect of miR‐224‐3p on apoptosis was partially blocked
when FIP200 was overexpressed [162]. A triterpenoid isolated from the
trametes lactinea (Berk.) Pat (a type of mushroom), Trametenolic acid B
(TAB) significantly reduced serum ROS levels, neuronal cell loss and
apoptosis in cerebral I/R injury rats [163]. The neuroprotective effect
of TAB against ODG/R and I/R injury seems to occur through miR-10a.
TAB downregulates miR-10a resulting in increased activation of the
PI3K/Akt/mTOR signaling pathway, which reduces mitochondrial-
mediated apoptosis [163]. Li et al. found that 115 circulating miRNAs
were differentially expressed in acute ischemic stroke, a form of cere-
bral I/R [164]. As such, several other miRNAs involved in cerebral I/R will
likely be identified in the next few years that alter the cellular redox
status of cells.
8. miRNAs involved in cellular redox status as potential targets
for therapeutics and biomarkers
The number of publications that suggest miRNAs would be quality
biomarkers for health conditions has significantly increased over the
last few years. As such, the promise of miRNAs being used in the
treatment of diseases is high. However, an FDA-approved miRNA for
the treatment of any illness is still a few years away. Most advanced
candidate miRNAs are now in phase 1 or phase 2 clinical trials. The
road to approval is long, and most miRNA candidates are typically
withdrawn during different stages of the clinical trials (clinicaltrials.
gov). Another type of RNA, single (siRNA), had clinical trials started in
2004 and the first siRNA drug was only approved in 2018 [165]. As of
April 2020, nearly 900 clinical research studies on miRNAs as bio-
markers or as interventional drugs has been conducted or started
(clinicaltrials.gov), with some (28 as of April 20th, 2020) of these trials
already being discontinued and some (17 as of April 20th, 2020)
withdrawn. miR-21, which when inhibited reduces ROS production, is
in phase 1 trial for Alport syndrome (https://clinicaltrials.gov/ct2/
show/NCT03373786) [166].
It is likely that a miRNA clinical biomarker will be approved before
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a miRNA is approved for treating disease since more than half of the
current studies are screening for biomarkers or secondary studies fo-
cusing on particular miRNAs for specific diseases such as preeclampsia.
While in some cases, one miRNA might be able to identify a specific
health outcome, it is more likely that health conditions will require
several for increased specificity of detection [167].
9. Conclusion
Oxidative stress is a key contributing factor to many diseases, in-
cluding cancer and cardiovascular disease. The number of publications
identifying new redox-sensitive miRNAs, as well as the roles of these
miRNAs is increasing at a dramatic pace. Our understanding of the
major targets of these redox-sensitive miRNAs has increased dramati-
cally, and a few targets such as Nrf2, SIRT1, and NF-κB have been
identified that are targets for multiple miRNAs. However, more ex-
perimental work is needed since miRNAs could have numerous targets
and understanding the effect of the miRNA on those targets, as well as
the function of these targets, is essential. Research is also needed to
further determine the crosstalk between miRNAs, ROS and diseases, as
well as to discover redox-sensitive miRNAs that are vital in many dis-
eases but are not currently being investigated. Discovering new redox-
sensitive miRNAs is likely to get easier as in silico-based approaches
show promise to identify new miRNA targets as well as miRNAs binding
to specific targets. miRNA disease association prediction will also
continue to improve [168].
While the rush is on to identify miRNA biomarkers of diseases and
to develop miRNA based therapeutic targets, the number of redox-
sensitive miRNAs in clinical trials is limited. Hence, the use of redox-
sensitive miRNAs for biomarkers of disease or as clinical therapeutics is
likely several years off as numerous studies are required to validate and
elaborate on current findings. Overall, redox-sensitive miRNAs have the
potential to allow us to regulate oxidative stress. Once our under-
standing of redox-sensitive miRNAs is detailed enough to allow us to
use individual or pools of miRNA modulating compounds safely, tar-
geting miRNAs will enable us to improve health-related outcomes as-
sociated with different diseases.
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